ADVM-022 for choroidal neovascularization

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Aug 2022: Trial started, NCT05536973
  2. 13 Sep 2022: Trial registered, NCT05536973

The trials

NCT05536973: Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

State
Under way
Phase
Phase 2
People
69 taking part
Started
23 Aug 2022
Primary completion
26 Aug 2024
Arms
Dose 1, Dose 2
Results
None posted
  1. 23 Aug 2022: Trial started
  2. 13 Sep 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.